Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Heinemann, Volker; Stintzing, Sebastian; Modest, Dominik Paul; Gießen-Jung, Clemens; Michl, Marlies; Mansmann, Ulrich

doi:10.1016/j.ejca.2015.06.116

Cited by 162 publications

(167 citation statements)

References 47 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…These results show that lenvatinib induced an early-on-treatment response within 8 weeks. This phenomenon is called ETS in other malignancies [10][11][12]. If this aspect plays a role in lenvatinib for thyroid carcinoma, ETS can be a surrogate marker of efficacy, making early imaging evaluation more meaningful.…”

Section: Discussionmentioning

confidence: 99%

Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma

et al. 2017

View full text Add to dashboard Cite

“…Statistically significant longer PFS and OS have been reported in patients with early tumor shrinkage ≥ 20% as compared to those without early shrinkage in several studies [24][25][26][27][28]. Early response was here associated with a non-statistically significant PFS prolongation by 2 months as compared to non-early response.…”

Section: Discussionmentioning

confidence: 66%

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

Bouchahda

Boige

Smith

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

2016) Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer Care, 68. pp. 163-172 Permanent WRAP URL: http://wrap.warwick.ac.uk/85119 Copyright and reuse:The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. Publisher's statement:"This is the peer reviewed version of the following article: Bouchahda, Mohamed, Boige, Valérie, Smith, Denis, Karaboué, Abdoulaye, Ducreux, Michel, Hebbar, Mohamed, Lepère, Céline, Focan, Christian, Guimbaud, Rosine, Innominato, Pasquale F. et al.. (2016) Early tumour response as a survival predictor in previously-treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer Care, 68. pp. 163-172 which has been published in final form at http://dx.doi.org/10.1016/j.ejca.2016.09.011 This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." A note on versions:The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL' above for details on accessing the published version and note that access may require a subscription. within a multicenter conversion-to-resection medico-surgical strategy. Confirmation is warranted for decision-making. Protocol numbersEUDRACT 2007-004632-24 NCT00852228 KEY WORDS:Early tumor response, colorectal cancer, liver metastases, hepatic artery infusion, triplet chemotherapy. ACKNOWLEDGEMENTS:We sincerely acknowledge the contribution of the patients who participated in this trial and all our colleagues and staff at the participating institutions.

show abstract

“…Проведенный метаанализ этих исследований показал, что добавление панитумумаба или цетуксимаба к химиотерапии ассоциировано со статистически значи-мым повышением частоты объективных ответов и про-должительности жизни, но не выживаемости без про-грессирования [26]. Также отмечено, что комбинации с анти-EGFR антителами приводят к более значимому уменьшению проявлений болезни в размерах, которое наступает раньше, чем на комбинациях с бевацизумабом [27,28]. Данное наблюдение послужило основой к реко-мендации применения комбинации анти-EGFR монокло-нальных антител совместно с химиотерапией в первой линии при диком типе генов RAS в случаях необходи-мости быстрого уменьшения размеров опухоли, то есть с целью циторедукции.…”

Section: какой таргетный препарат выбрать в первой линии леченияunclassified

Optimal Sequences and Combination of Chemotherapy and Monoclonal Antibodies in the Treatment of Patients With Metastatic Colorectal Cancer

Федянин¹,

Тюляндин²

2018

Zlokač. opuholi

View full text Add to dashboard Cite

In this review we analyzed results of studies concerning the choice of first and subsequent lines of therapy in patients with metastatic colon cancer. We discussed data of various combinations of monoclonal antibodies with different chemotherapeutic regimens. Also we discussed modern preclinical and clinical trials concerning strategy of choice of targeted therapy sequence in patients with metastatic disease. We considered the impact of various molecular and clinical factors on the effectiveness of drugs and determined their application for therapy choice for colon cancer.

show abstract

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Cited by 162 publications

References 47 publications

Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma

Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer

Optimal Sequences and Combination of Chemotherapy and Monoclonal Antibodies in the Treatment of Patients With Metastatic Colorectal Cancer

Contact Info

Product

Resources

About